NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹1,681 Cr | ₹944 Cr | ₹973 Cr | ₹683 Cr | ₹710 Cr |
What is the latest Total Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹1,681 Cr |
| Mar2025 | ₹944 Cr |
| Mar2024 | ₹973 Cr |
| Mar2023 | ₹683 Cr |
| Mar2022 | ₹710 Cr |
How is Total Current Liabilities of NATCO PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,681 Cr | 78.16 | |
| Mar2025 | ₹944 Cr | -3.01 | |
| Mar2024 | ₹973 Cr | 42.41 | |
| Mar2023 | ₹683 Cr | -3.84 | |
| Mar2022 | ₹710 Cr | - | |
Compare Total Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹15,018.4 Cr | -1.3% | -8.6% | -4.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,826.0 Cr | -1.6% | -2.5% | 21.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹247,019.0 Cr | 1.5% | 12.8% | 48.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,875.0 Cr | -0.9% | -0.8% | 35.3% | Stock Analytics | |
| CIPLA | ₹112,773.0 Cr | -1.6% | -5.2% | -11.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,570.9 Cr | -2.2% | -2.3% | -8.2% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -1.3% |
-8.6% |
-4.2% |
| SENSEX | -1.1% |
-3.6% |
-5.3% |
You may also like the below Video Courses